Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report

INTRODUCTION: Febuxostat, a nonpurine xanthine oxidase inhibitor, is approved as the first-line urate-lowering therapy in gout patients with normal renal function or mild to moderate renal impairment. The most common adverse effects of febuxostat are liver function test abnormalities, diarrhea, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Poh, Xue Er, Lee, Chien-Te, Pei, Sung-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266183/
https://www.ncbi.nlm.nih.gov/pubmed/28079821
http://dx.doi.org/10.1097/MD.0000000000005863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266183/
https://www.ncbi.nlm.nih.gov/pubmed/28079821
http://dx.doi.org/10.1097/MD.0000000000005863

Ejemplares similares